Advertisement

Tumor Biology

, Volume 36, Issue 2, pp 533–541 | Cite as

Krüppel-like factors in hepatocellular carcinoma

  • Xiao-Jie Lu
  • Yan Shi
  • Jin-Lian Chen
  • Shijie Ma
Review

Abstract

Hepatocellular carcinoma (HCC) is a disease with a high incidence and mortality rate worldwide. However, the mechanisms underlying its pathogenesis are still elusive. In recent years, studies on functions of Krüppel-like factors (KLFs) in HCC have shed new light on this field. To date, five members (KLF4, KLF6, KLF8, KLF9, and KLF17) in the KLF family have been reported to function in the pathogenesis of HCC in multiple ways, which hold the potential of deepening and widening our understanding in the initiation and progression of HCC. In this review, we focus on the functions, roles, and regulatory networks of these five KLFs in HCC, summarize key pathways, and propose areas for further investigation, with the hope that this review will provide a reliable and concise reference for readers interested in this area.

Keywords

Hepatocellular carcinoma Krüppel-like factor Tumor suppressor gene Oncogene 

Notes

Acknowledgments

National High Technology Research (863) Project of China (2012AA020204).

Conflicts of interest

None

References

  1. 1.
    Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins. Mol Cell Biol. 1993;13:2776–86.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nuez B, Michalovich D, Bygrave A, Ploemacher R, Grosveld F. Defective haematopoiesis in fetal liver resulting from inactivation of the EKLF gene. Nature. 1995;375:316–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Perkins AC, Sharpe AH, Orkin SH. Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature. 1995;375:318–22.CrossRefPubMedGoogle Scholar
  4. 4.
    McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev. 2010;90:1337–81.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kaczynski J, Cook T, Urrutia R. Sp1- and Krüppel-like transcription factors. Genome Biol. 2003;4(2):206.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005;65(4):1213–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Chakroborty D, Sarkar C, Yu H, Wang J, Liu Z, Dasgupta PS, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011;108:20730–5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Taniguchi H, Jacinto FV, Villanueva A, Fernandez AF, Yamamoto H, Carmona FJ, et al. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene. 2012;31:1988–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Yang Y, Nakagawa H, Tetreault MP, Billig J, Victor N, Goyal A, et al. Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res. 2011;71:6475–84.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Meyer SE, Hasenstein JR, Baktula A, Velu CS, Xu Y, Wan H, et al. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better. Am J Pathol. 2010;177(3):1503–13.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chang VH, Chu PY, Peng SL, Mao TL, Shan YS, Hsu CF, et al. Kruppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma. Am J Pathol. 2012;181:423–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, Lerman MI. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun. 2008;370:536–40.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118–28.CrossRefPubMedGoogle Scholar
  15. 15.
    Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMedGoogle Scholar
  16. 16.
    McConnell BB, Ghaleb AM, Nandan MO, Yang VW. The diverse functions of Kruppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays. 2007;29:549–57.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Valencia-Hipόlito A, Hernández-Atenógenes M, Vega GG, Maldonado-Valenzuela A, Ramon G, Mayani H, et al. Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. Leuk Lymphoma. 2014;55(8):1806–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Yang Y, Goldstein BG, Chao HH, Katz JP. KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 2005;4:1216–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene. 2004;23:395–402.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, et al. Drastic downregulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005;65:2746–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y, et al. Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun. 2003;308:251–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Zammarchi F, Morelli M, Menicagli M, Di Cristofano C, Zavaglia K, Paolucci A, et al. KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J Pathol. 2011;178:361–72.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hu W, Hofstetter WL, Li H, Zhou Y, He Y, Pataer A, et al. Putative tumor suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res. 2009;15:5688–95.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, et al. Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia. 2010;12:20–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yin X, Li YW, Jin JJ, Zhou Y, Ren ZG, Qiu SJ, et al. The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma. Oncol Lett. 2013;5(4):1155–62.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hsu HT, Wu PR, Chen CJ, Hsu LS, Yeh CM, Hsing MT, et al. High cytoplasmic expression of Krüppel-like factor 4 is an independent prognostic factor of better survival in hepatocellular carcinoma. Int J Mol Sci. 2014;15(6):9894–906.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lin ZS, Chu HC, Yen YC, Lewis BC, Chen YW. Kruppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS ONE. 2012;7(8):e43593.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Li Q, Gao Y, Jia Z, Mishra L, Guo K, Li Z, et al. Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology. 2012;143:799–810.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Matsumoto N, Kubo A, Liu H, Akita K, Laub F, Ramirez F, et al. Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood. 2006;107:1357–65.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Bureau C, Hanoun N, Torrisani J, Vinel JP, Buscail L, Cordelier P. Expression and function of Kruppel like-factors (KLF) in carcinogenesis. Curr Genomics. 2009;10:353–60.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat. 2009;12(1–2):1–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Andreoli V, Gehrau RC, Bocco JL. Biology of Krüppel-like factor 6 transcriptional regulator in cell life and death. IUBMB Life. 62(12):896–905.Google Scholar
  33. 33.
    Tetreault MP, Yang Y, Katz JP. Krüppel-like factors in cancer. Nat Rev Cancer. 2013;13(10):701–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, et al. Enhanced hepatocarcinogenesis in mouse models and human HCC by coordinate KLF6 depletion and increased mRNA Splicing. Hepatology. 2012;56:1361–70.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res. 2012;10:1216–27.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhenzhen Z, De’an T, Limin X, Wei Y, Min L. New candidate tumor-suppressor gene KLF6 and its splice variant KLF6 SV2 counterbalancing expression in primary hepatocarcinoma. Hepatogastroenterology. 2012;59:473–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Hanoun N, Bureau C, Diab T, Gayet O, Dusetti N, Selves J, et al. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. J Hepatol. 2010;53:880–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Sirach E, Bureau C, Péron JM, Pradayrol L, Vinel JP, Buscail L, et al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ. 2007;14:1202–10.CrossRefPubMedGoogle Scholar
  39. 39.
    Bureau C, Péron JM, Bouisson M, Danjoux M, Selves J, Bioulac-Sage P, et al. Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:78–86.CrossRefPubMedGoogle Scholar
  40. 40.
    Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology. 2004;40(5):1047–52.CrossRefPubMedGoogle Scholar
  41. 41.
    Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol. 2007;46(4):645–54.CrossRefPubMedGoogle Scholar
  42. 42.
    Wang SP, Zhou HJ, Chen XP, Ren GY, Ruan XX, Zhang Y, et al. Loss of expression of Kruppel-like factor 6 in primary hepatocellular carcinoma and hepatoma cell lines. J Exp Clin Cancer Res. 2007;26(1):117–24.PubMedGoogle Scholar
  43. 43.
    Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene. 2007;26:4428–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Lee UE, Ghiassi-Nejad Z, Paris AJ, Yea S, Narla G, Walsh M, et al. Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett. 2010;584:1006–10.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Wang S, Kang L, Chen X, Zhou H. Frequent down-regulation and deletion of KLF6 in primary hepatocellular carcinoma. J Huazhong Univ Sci Technol. 2010;30:470–6.CrossRefGoogle Scholar
  46. 46.
    Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, et al. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma, associated with p53 pathway deregulation. Hepatology. 2011;54:522–31.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Boyault S, Hérault A, Balabaud C, Zucman-Rossi J. Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology. 2005;41(3):681–2.CrossRefPubMedGoogle Scholar
  48. 48.
    Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH, et al. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21(8):1286–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 2008;134(5):1521–31.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Lang UE, Kocabayoglu P, Cheng GZ, Ghiassi-Nejad Z, Muñoz U, Vetter D, et al. GSK3b phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene. 2013;32:4557–64.CrossRefPubMedGoogle Scholar
  51. 51.
    Diab T, Hanoun N, Bureau C, Christol C, Buscail L, Cordelier P, et al. The role of the 3' untranslated region in the post-transcriptional regulation of KLF6 gene expression in hepatocellular carcinoma. Cancer (Basel). 2013;6:28–41.CrossRefGoogle Scholar
  52. 52.
    Li JC, Yang XR, Sun HX, Xu Y, Zhou J, Qiu SJ, et al. Up-regulation of Krüppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology. 2010;139:2146–57.CrossRefPubMedGoogle Scholar
  53. 53.
    Yang T, Cai SY, Zhang J, Lu JH, Lin C, Zhai J, et al. Kruppel-like factor 8 is a new Wnt/Beta-catenin signaling target gene and regulator in hepatocellular carcinoma. PLoS ONE. 2012;7(6):e39668.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Fu DZ, Cheng Y, He H, Liu HY, Liu YF. The fate of Krüppel-like factor 9-positive hepatic carcinoma cells may be determined by the programmed cell death protein 5. Int J Oncol. 2014;44:153–60.PubMedGoogle Scholar
  55. 55.
    Sun J, Wang B, Liu Y, Zhang L, Ma A, Yang Z, et al. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Lett. 2014;355(1):25–33.CrossRefPubMedGoogle Scholar
  56. 56.
    Liu FY, Deng YL, Li Y, Zeng D, Zhou ZZ, Tian DA, et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol. 2013;30:425.CrossRefPubMedGoogle Scholar
  57. 57.
    Sun Z, Han Q, Zhou N, Wang S, Lu S, Bai C, et al. MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Mol Oncol. 2013;7:884–94.CrossRefPubMedGoogle Scholar
  58. 58.
    Li W, Ni GX, Zhang P, Zhang ZX, Li W, Wu Q. Characterization of E2F3a function in HepG2 liver. Cancer Cells. J Cell Biochem. 2010;111:1244–51.CrossRefPubMedGoogle Scholar
  59. 59.
    Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics. 2006;7:268.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Zhou W, Zeng X, Liu T. Aberrations of chromosome 13q in gastrointestinal stromal tumors: analysis of 91 cases by fluorescence in situ hybridization (FISH). Diagn Mol Pathol. 2009;18:72–80.CrossRefPubMedGoogle Scholar
  61. 61.
    Soon MS, Hsu LS, Chen CJ, Chu PY, Liou JH, Lin SH, et al. Expression of Kruppel-like factor 5 in gastric cancer and its clinical correlation in Taiwan. Virchows Arch. 2011;459:161–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Nandan MO, Ghaleb AM, McConnell BB, Patel NV, Robine S, Yang VW. Kruppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations. Mol Cancer. 2010;9:63.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Mori A, Moser C, Lang SA, Hackl C, Gottfried E, Kreutz M, et al. Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. Mol Cancer Res. 2009;7:1390–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Diakiw SM, Perugini M, Kok CH, Engler GA, Cummings N, To LB, et al. Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. Br J Haematol. 2013;61(6):884–8.CrossRefGoogle Scholar
  65. 65.
    Takagi K et al. Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocr Relat Cancer. 2012;19:741–50.CrossRefPubMedGoogle Scholar
  66. 66.
    Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008;20(6):32.CrossRefGoogle Scholar
  67. 67.
    Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D, et al. Effect of common B-RAF and NRAS mutations on global gene expression in melanoma cell lines. Carcinogenesis. 2005;26:1224–32.CrossRefPubMedGoogle Scholar
  68. 68.
    Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate. 2003;55:81–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, et al. Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2004;86:75–88.CrossRefPubMedGoogle Scholar
  70. 70.
    Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J. 2003;22:4748–58.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Potapova A, Hasemeier B, Römermann D, Metzig K, Göhring G, Schlegelberger B, et al. Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes. Eur J Haematol. 2010;84:298–303.CrossRefPubMedGoogle Scholar
  72. 72.
    Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S, et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 2012;26:4937–50.CrossRefPubMedGoogle Scholar
  73. 73.
    Nakamura Y, Migita T, Hosoda F, Okada N, Gotoh M, Arai Y, et al. Kruppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression. Int J Cancer. 2009;125:1859–67.CrossRefPubMedGoogle Scholar
  74. 74.
    Giefing M, Wierzbicka M, Rydzanicz M, Cegla R, Kujawski M, Szyfter K. Chromosomal gains and losses indicate oncogene and tumor suppressor gene candidates in salivary gland tumors. Neoplasma. 2008;55(1):55–60.PubMedGoogle Scholar
  75. 75.
    Henson BJ, Gollin SM. Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet Genome Res. 2010;128:192–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Gastroenterology, Shanghai East HospitalTongji University School of MedicineShanghaiChina
  2. 2.Department of EmergencyThe Affiliated Huai’an Hospital of Xuzhou Medical College and The Second People’s Hospital of Huai’anHuai’anChina
  3. 3.Department of Gastroenterology, Shanghai Sixth People’s Hospital (South)Shanghai Jiaotong University School of MedicineShanghaiChina
  4. 4.Department of Gastroenterology, Huai’an First People’s HospitalNanjing Medical UniversityHuai’anChina

Personalised recommendations